Abstract
(Abstracted from Obstet Gynecol 2016;128:476–485) There is a clear survival benefit for prophylactic oophorectomy in patients with inherently higher cancer risk such as those with BRCA1 and BRCA2 and other genetic mutations. For average-risk women, however, cancer risk reduction must be balanced with the consequences of loss of ovarian hormone production and fertility.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
